Sellas Life Sciences Group Inc. announced an update on its ongoing Phase 3 REGAL trial evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with acute myeloid leukemia (AML) following second complete remission. As of December 26, 2025, 72 events have occurred in the study, according to the contract research organization managing the trial. The company remains blinded to all efficacy and survival outcomes, and no analyses have been performed. The final analysis will be conducted once the 80th event occurs, at which time results will be announced. Results from the trial have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9617363-en) on December 29, 2025, and is solely responsible for the information contained therein.